Sensorion Logo

Sensorion

ALSEN | PA

Overview

Corporate Details

ISIN(s):
FR0012596468 (+2 more)
LEI:
969500P0W8XJ9CGZDP97
Country:
France
Address:
375 RUE DU PROFESSEUR BLAYAC, 34080 MONTPELLIER
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Sensorion is a clinical-stage biotechnology company specializing in the development of novel therapies for inner ear disorders. The company's mission is to address significant unmet medical needs by developing treatments to restore, treat, and prevent hearing loss, vertigo, and tinnitus. Its strategy is structured around three pillars: 'Restore,' which focuses on gene therapies for genetic forms of hearing loss; 'Treat,' which develops small molecule solutions for existing conditions; and 'Prevent,' which aims to protect against non-genetic hearing loss (e.g., drug- or surgery-induced). Sensorion utilizes a unique R&D technology platform to advance its understanding of inner ear disease pathophysiology and collaborates with partners, including the Institut Pasteur, to build its therapeutic pipeline.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Sensorion. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-15 07:30
Capital/Financing Update
Inside Information / Other news releases
English 139.2 KB
2025-08-15 07:30
Capital/Financing Update
Informations privilégiées / Autres communiqués
French 140.2 KB
2025-07-29 07:30
Legal Proceedings Report
Inside Information / Other news releases
English 188.2 KB
2025-07-29 07:30
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-07-01 07:30
Earnings Release
Inside Information / Other news releases
English 187.9 KB
2025-07-01 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 194.8 KB
2025-05-13 07:30
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 133.2 KB
2025-05-13 07:30
Post-Annual General Meeting Information
Inside Information / Other news releases
English 139.4 KB
2025-05-06 07:30
Regulatory News Service
Inside Information / Other news releases
English 180.6 KB
2025-05-06 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 176.8 KB
2025-04-25 07:30
Regulatory News Service
Inside Information / Other news releases
English 151.9 KB
2025-04-25 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 171.2 KB
2025-04-18 09:24
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 163.1 KB
2025-04-18 09:24
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 137.5 KB
2025-04-16 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 165.8 KB

Automate Your Workflow. Get a real-time feed of all Sensorion filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Sensorion via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-11 N/A Other Other 2,781,914 1,752,605.82 EUR
2024-04-11 N/A Other Other 1,587,301 999,999.63 EUR
2024-02-13 N/A Other Other 16,842,105 9,599,999.85 EUR
2024-02-08 N/A Other Other 12,280,701 6,999,999.57 EUR
2023-08-08 N/A Other Other 46,428,571 12,999,999.88 EUR
2023-08-03 N/A Other Other 25,000,000 7,000,000.00 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN